New DNA-based vaccine scaffolds boost targeted immune responses to HIV Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breastfeeding Cold, Flu & Cough Dermatology Diabetes Eating Disorders Eye Health Gastrointestinal Health Heart Disease Lung Cancer Mental Health Parkinson's Disease Pregnancy Sleep Urology View Health A-Z × Top Health Categories Coronavirus Disease COVID-19 Eating Disorders Diet & Nutrition Eye Health Artificial Intelligence Gastrointestinal Health Allergies Heart Disease Alzheimer's & Dementia Lung Cancer Arthritis & Rheumatology Mental Health Breast Cancer Parkinson's Disease Breastfeeding Pregnancy Cold, Flu & Cough Sleep Dermatology Urology Diabetes View Health A-Z Medical Home Life Sciences Home About News Life Sciences A-Z White Papers Lab Equipment Interviews Newsletters Webinars More... eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member White Papers MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Webinars eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member New DNA-based vaccine scaffolds boost targeted immune responses to HIV Download PDF Copy Reviewed Scripps Research Institute Feb 6 2026 One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and antibodies. In most vaccines, HIV proteins are attached to a larger protein scaffolding that mimics a virus. Then, a person's immune system produces a range of antibodies that recognize different bits of those proteins. Often, however, some of those antibodies react not to HIV itself-but to the scaffold used to deliver the vaccine. Now, researchers at Scripps Research and the Massachusetts Institute of Technology (MIT) have developed a new kind of vaccine scaffolding made from DNA that the immune system ignores, eliminating these off-target antibodies. In a new study published in Science on February 5, 2026, the team showed that vaccines made with these DNA-based scaffolds led to 10 times more immune cells targeting a vulnerable site on HIV when compared to vaccines with protein-based scaffolds. That suggests a stronger and more targeted immune response to the DNA-based vaccines . It's a brand-new technology that might help us get to a protective HIV vaccine or solve other particularly difficult vaccine problems." Darrell Irvine, senior author, professor at Scripps Research Typically, a vaccine is made up of a scaffolding particle covered in many inert viral proteins (antigens) that can be recognized by the immune system. Like a virus, these vaccine structures present many copies of an antigen on their surface, triggering stronger immune activation than free-floating antigens used in previous, less effective vaccines. But until now, essentially all such scaffolds have been made from proteins, which can trigger immune reactions to the scaffolds themselves. For most vaccines targeting common pathogens, the off-target immune reaction doesn't pose major problems. But for challenging vaccine targets like HIV, influenza and pan-coronavirus vaccines-where broadly protective B cells are extraordinarily rare-every competing immune response could matter. "We knew that protein nanoparticle scaffolds generate their own immune responses, but we didn't know how much those off-target responses were actually limiting the immune cells we care about," says Irvine, who is also a Howard Hughes Medical Institute Investigator. In the new work, Irvine, along with lead author Anna Romanov and collaborators including biological engineer Mark Bathe of MIT, turned to DNA origami technology, which allows scientists to fold DNA into precise three-dimensional shapes. There's limited data regarding the use of DNA origami in vaccines, but the researchers already knew that B cells-the immune cells responsible for recognizing antigens and producing antibodies-don't flag DNA. That's in part to protect people from autoimmune reactions attacking their own DNA. "In prior work in 2024 using a SARS-CoV-2 antigen, we found DNA scaffolds were 'silent' immunologically without generating an antibody response, but it was unclear whether they'd also promote focused germinal center responses; this study now clearly demonstrates this response for Scripps' HIV antigen, which is a breakthrough for the active immunotherapy field," says Bathe. Related Stories Sino Biological expands research reagent portfolio to support global Nipah virus vaccine and diagnostic development Gut microbial butyrate enhances mucosal vaccine antibody responses COVID vaccination not linked to reduced childbirth The team designed DNA nanoparticles that could each display 60 copies of an HIV envelope protein-one that's known to activate the rare B cells that can eventually produce broadly neutralizing antibodies against HIV . They then tested the nanoparticles in mice expressing human antibody genes. Nearly 60% of the germinal center B cells-specialized immune cells that mature to produce the high-quality antibodies-targeted the HIV envelope protein. By contrast, the protein-scaffolded vaccine (which is currently in clinical trials) generated germinal centers where only about 20% of B cells recognized the HIV target; the rest included many cells responding to the scaffold itself. The DNA-based vaccine achieved a 25-fold better ratio of HIV-specific to off-target immune cells compared to the protein scaffold. Within two weeks of vaccination, mice who had received the DNA-based vaccine had detectable levels of the desired rare B cells, while mice who had received the protein nanoparticle-based vaccine had none of the cells detectable. The implications extend beyond HIV, as the same challenges apply to efforts to develop universal influenza and pan-coronavirus vaccines. DNA origami scaffolds could provide a more focused immune response for any of these challenging vaccine problems, says Irvine. "These are vaccines where you're trying to recruit incredibly rare cells in the B-cell repertoire," he adds. "Anything that limits those correct cells from getting activated is a potential problem, and DNA origami scaffolds could help overcome these challenges." The Irvine and Bathe teams are now studying how variations in the shape of the DNA origami may impact vaccine effectiveness, as well as testing the long-term safety of the scaffolds for vaccination. Source: Scripps Research Institute Journal reference: Romanov, A., et al. (2026). DNA origami vaccines program antigen-focused germinal centers. Science . DOI: 10.1126/science.adx6291. https://www.science.org/doi/10.1126/science.adx6291 Posted in: Medical Science News | Disease/Infection News Comments (0) Download PDF Copy Suggested Reading Her son’s injury never got its day in vaccine court. Their lawyer is now advising RFK on its overhaul. Single-dose HIV vaccine candidate induces neutralizing antibodies Enhanced natural killer cells show promise for HIV remission Griffith researchers on the cusp of new vaccine to prevent chikungunya Study suggests shingles vaccine may help lower Alzheimer’s and dementia risk Early tuberculosis treatment reduces sepsis deaths in HIV patients Nasal spray vaccine prevents infection from highly pathogenic H5N1 virus Binghamton University receives $2.5 million to develop a next-generation avian flu vaccine Comments The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical. Cancel reply to comment Post a new comment Login (Logout) Quirky Comment Title Post Trending Stories Latest Interviews Top Health Articles Cognitive speed training shows potential to delay dementia for two decades Gut bacteria use formic acid as an electron taxi Metformin linked to lower odds of intermediate macular degeneration in people with diabetes Influenza D virus and canine coronavirus pose human risks New DNA-based vaccine scaffolds boost targeted immune responses to HIV Advancing brain microphysiological systems (bMPS) Dr. Lena Smirnova Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. PhD researcher at LifeArc Natasha Bury Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative approaches for gram-negative bacteria. Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research Rosanna Zhang In our latest interview, News-Medical speaks with Rosanna Zhang from ACROBiosystems about utilizing organoids for disease modeling in the field of neuroscience research. Astaxanthin and Human Health: Evidence on Skin, Vision, Brain, and Aging The Gut–Brain–Skin Axis: How Diet and Gut Health Influence Mood, Skin, and Aging How to Safely Return to Exercise After Prolonged Physical Inactivity How Morning Routines Influence Cognitive Performance, Mood, and Circadian Rhythm Dry January: Key Health Benefits of 30 Days Without Alcohol Latest News Promising new speech biomarker could enrich antipsychotic clinical trials Early heart disease risk factors identified in South Asian adults in the U.S. Simple wrist-worn device enables early detection of depression relapse Rural cancer patients benefit from local surgical care Healthy low-carbohydrate and low-fat diets may improve cardiovascular health Newsletters you may be interested in HIV/AIDS ( Subscribe or Preview ) Nanomedicine ( Subscribe or Preview ) COVID-19 ( Subscribe or Preview ) See all Newsletters » High Credibility: This website adheres to all nine standards of credibility and transparency. Medical Links Medical Home Functional Food News Health A-Z White Papers Thought Leaders Insights MediKnowledge Series Health & Personal Care Medical Devices Drugs eBooks Posters Podcasts Life Sciences Links Life Sciences Home News Lab Instruments & Equipment Life Sciences A-Z White Papers Thought Leaders Insights Webinars eBooks Posters Podcasts Other Useful Links About Meet the Team Search Newsletters Sitemap Advertise Contact Terms & Conditions Privacy & Cookie Policy Content Policy Ownership & Funding Information Other AZoNetwork Sites AZoM AZoNano AZoCleantech AZoOptics AZoRobotics AZoSensors AZoMining AZoQuantum AZoBuild AZoLifeSciences AZoAi Facebook Twitter LinkedIn News-Medical.Net provides this medical information service in accordance with these terms and conditions . Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Update Your Privacy Preferences Last Updated: Wednesday 11 Feb 2026 News-Medical.net - An AZoNetwork Site Owned and operated by AZoNetwork, © 2000-2026 Azthena logo with the word Azthena Maximise chat window Hide chat window Your AI Powered Scientific Assistant Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. To start a conversation, please log into your AZoProfile account first, or create a new account. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content . Log in A few things you need to know before we start. Please read and accept to continue. Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI . Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy . Large Language Models can make mistakes. Consider checking important information. I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements. Please check the box above to proceed. Start Chat Great. Ask your question. Clear Chat Clear Chat Brief Moderate Detailed Azthena may occasionally provide inaccurate responses. Read the full terms . Terms While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information. Read the full Terms & Conditions . Provide Feedback Submit Cancel You might also like... × Two-pronged therapeutic technology for cancer wins Pfizer Prize for Biomedical Research 2026